IL13 and asthma: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling via IL-4Rα inhibition, has emerged as an effective treatment for CRSwNP and asthma, offering significant reductions in nasal polyp burden, improvements in quality of life, and better asthma control.3